Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Nov 13, 2018. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Amended on Nov 15, 2018 – the version known today is shown.

You are looking at Q3 2018. Go to the latest filing (Q3 2026)

12.7B USDQ3 2018
Total value of stock positions
12.7B USD
Positions
36
Share of the ten largest
74.0%

The ten largest positions Q3 2018

  1. Twenty First Centy Fox Inc 18.9%▲ +31.9%
  2. Cheniere Energy Inc 7.8%unchanged
  3. Allergan PLC 7.4%unchanged
  4. Viasat Inc 6.9%unchanged
  5. PG&E Corporation 6.9%▲ +321.8%
  6. Qorvo Inc 6.7%unchanged
  7. Twenty First Centy Fox Inc 6.2%▲ +27.3%
  8. Pioneer Nat Res Co 5.5%unchanged
  9. Synchrony Financial 4.0%▼ −44.2%
  10. Antero Res Corp 3.7%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q3 2018

Positions Q3 2018 per 13F filing, 36 of 36
Symbol Weight Shares Reported value Change Held since
Twenty First Centy Fox Inc 18.9% 52,001,167 2.4B USD +31.9% increased Q3 2015 13 quarters
Cheniere Energy Inc 7.8% 14,196,135 986.5M USD unchanged Q1 2014 19 quarters
Allergan PLC 7.4% 4,950,000 942.9M USD unchanged Q1 2016 11 quarters
Viasat Inc 6.9% 13,732,068 878.2M USD unchanged Q2 2013 or earlier 22 quarters
PCG PG&E Corporation 6.9% 18,979,790 873.3M USD +321.8% increased Q1 2018 3 quarters
Qorvo Inc 6.7% 11,000,000 845.8M USD unchanged Q1 2017 7 quarters
Twenty First Centy Fox Inc 6.2% 17,320,922 793.6M USD +27.3% increased Q3 2015 13 quarters
Pioneer Nat Res Co 5.5% 4,000,000 696.8M USD unchanged Q3 2017 5 quarters
SYF Synchrony Financial 4.0% 16,332,929 507.6M USD −44.2% reduced Q3 2016 9 quarters
Antero Res Corp 3.7% 26,587,791 470.9M USD unchanged Q3 2014 17 quarters
Theravance Biopharma Inc 2.4% 9,309,168 304.1M USD unchanged Q2 2014 18 quarters
Liberty Global PLC 2.4% 10,768,870 303.3M USD new Q3 2018 1 quarter
Colony Cap Inc New 2.4% 49,687,370 302.6M USD unchanged Q2 2018 2 quarters
MCK McKesson Corporation 2.3% 2,175,700 288.6M USD +33.7% increased Q3 2017 5 quarters
Atara Biotherapeutics Inc 2.0% 6,254,632 258.6M USD unchanged Q4 2014 16 quarters
CAH Cardinal Health 2.0% 4,738,485 255.9M USD −7.1% reduced Q4 2016 8 quarters
COR Cencora 2.0% 2,751,056 253.7M USD +46.8% increased Q3 2017 5 quarters
Tribune Media Co 1.8% 5,996,042 230.4M USD +100.1% increased Q2 2018 2 quarters
Altaba Inc 1.5% 2,810,775 191.5M USD new Q3 2018 1 quarter
Liberty Global PLC 1.1% 4,957,205 143.4M USD new Q3 2018 1 quarter
Veritiv Corp 1.0% 3,564,439 129.7M USD −6.8% reduced Q3 2014 17 quarters
Ypf Sociedad Anonima 0.7% 6,000,000 92.7M USD new Q3 2018 1 quarter
Keryx Biopharmaceuticals Inc 0.7% 25,791,678 87.7M USD unchanged Q1 2014 19 quarters
Sinclair Broadcast Group Inc 0.7% 3,000,000 85.1M USD +16.7% increased Q2 2018 2 quarters
Translate Bio Inc 0.5% 6,491,287 62.4M USD +237.5% increased Q2 2018 2 quarters
AMC AMC Entertainment 0.4% 2,731,300 56.0M USD −45.4% reduced Q3 2017 5 quarters
Univar Inc 0.4% 1,771,100 54.3M USD new Q3 2018 1 quarter
Novagold Res Inc 0.4% 13,467,145 50.0M USD unchanged Q2 2013 or earlier 22 quarters
Gty Technology Holdings Inc 0.4% 4,400,000 47.6M USD unchanged Q4 2016 8 quarters
Trilogy Metals Inc New 0.2% 13,050,758 26.0M USD unchanged Q3 2016 9 quarters
Saban Cap Acquisition Corp 0.2% 2,326,500 23.6M USD unchanged Q4 2016 8 quarters
Paratek Pharmaceuticals Inc 0.2% 2,394,498 23.2M USD unchanged Q4 2014 16 quarters
Shire PLC 0.1% 98,932 17.9M USD unchanged Q2 2018 2 quarters
Sentinel Energy Svcs Inc 0.1% 1,600,000 16.4M USD unchanged Q4 2017 4 quarters
Nexeo Solutions Inc < 0.1% 2,850,000 2.9M USD new Q3 2018 1 quarter
Saban Cap Acquisition Corp < 0.1% 1,163,250 1.3M USD unchanged Q4 2016 8 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 343.1M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Tesla Inc principal 300.0M USD 308.6M USD
  • Theravance Biopharma Inc principal 30.0M USD 34.6M USD

Breakdown by sector

  • Utilities 6.9%
  • Health Care 6.3%
  • Financials 4.0%
  • Communication Services 0.4%
  • not in our coverage 82.4%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close